mitoxantrone

Summary

Summary: An anthracenedione-derived antineoplastic agent.

Top Publications

  1. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
  2. ncbi Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Daniel P Petrylak
    Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
    N Engl J Med 351:1513-20. 2004
  3. ncbi Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    Johann Sebastian de Bono
    Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK
    Lancet 376:1147-54. 2010
  4. ncbi Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
  5. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
    Dominik R Berthold
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    J Clin Oncol 26:242-5. 2008
  6. ncbi Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
    Fred Saad
    CRCUM Université de Montréal, Hamilton, Ontario, Canada
    Clin Cancer Res 17:5765-73. 2011
  7. pmc Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells
    Yanlin Li
    Department of Pharmacology, China Medical University, Shenyang City, Liaoning, China
    PLoS ONE 7:e44254. 2012
  8. ncbi Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux
    Charles S Morrow
    Department of Biochemistry, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Mol Pharmacol 69:1499-505. 2006
  9. ncbi Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study
    P W Kantoff
    Lank Center for Genitourinary Oncology and Breast Oncology Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 6084, USA
    J Clin Oncol 17:2506-13. 1999
  10. ncbi Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells
    Y Honjo
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:6635-9. 2001

Research Grants

  1. Mechanism of action of TOP2-directed anticancer drugs
    Leroy F Liu; Fiscal Year: 2012
  2. TARGETING AML-STROMAL INTERACTIONS
    John F DiPersio; Fiscal Year: 2013
  3. Targeting Leukemia Stromal Interactions in AML
    Geoffrey L Uy; Fiscal Year: 2013
  4. Optical Imaging of Chemotherapy for Brain Tumors
    Shailendra Joshi; Fiscal Year: 2013
  5. Cytoplasmic Reactivation of p53 Family Members
    Charles Walker; Fiscal Year: 2004
  6. MUTAGENIC ACTION OF CANCER THERAPY ON TESTIS CELLS
    Marvin Meistrich; Fiscal Year: 1992
  7. MODULATION OF MULTIDRUG RESISTANCE MECHANISMS
    Branimir Sikic; Fiscal Year: 2002
  8. NEW MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER CELLS
    Erasmus Schneider; Fiscal Year: 2001
  9. PULSE THERAPY TRIAL IN BETA INTERFERON RESISTANT ACTIVE
    Derek Smith; Fiscal Year: 2003
  10. DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
    Daniel Sullivan; Fiscal Year: 1992

Detail Information

Publications314 found, 100 shown here

  1. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
    b>Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival...
  2. ncbi Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Daniel P Petrylak
    Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
    N Engl J Med 351:1513-20. 2004
    b>Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer...
  3. ncbi Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    Johann Sebastian de Bono
    Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK
    Lancet 376:1147-54. 2010
    ..We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after ..
  4. ncbi Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
    ..To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial...
  5. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
    Dominik R Berthold
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    J Clin Oncol 26:242-5. 2008
    The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC)...
  6. ncbi Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
    Fred Saad
    CRCUM Université de Montréal, Hamilton, Ontario, Canada
    Clin Cancer Res 17:5765-73. 2011
    ..This study tested custirsen, a CLU inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or within 6 months of initial docetaxel therapy...
  7. pmc Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells
    Yanlin Li
    Department of Pharmacology, China Medical University, Shenyang City, Liaoning, China
    PLoS ONE 7:e44254. 2012
    ..this study, we examined the effects and mechanisms of FANCF-RNAi on the sensitivity of breast cancer cells to mitoxantrone (MX)...
  8. ncbi Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux
    Charles S Morrow
    Department of Biochemistry, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Mol Pharmacol 69:1499-505. 2006
    ..relationship between multidrug resistance protein 1 (MRP1, ABCC1) expression and cellular sensitivity to mitoxantrone (MX) toxicity can be ascertained; thus, the role of MRP1 in MX resistance remains controversial...
  9. ncbi Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study
    P W Kantoff
    Lank Center for Genitourinary Oncology and Breast Oncology Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 6084, USA
    J Clin Oncol 17:2506-13. 1999
    ..Corticosteroids and mitoxantrone each have been shown to be active agents in this disease...
  10. ncbi Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells
    Y Honjo
    Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:6635-9. 2001
    ..noted in the transport of rhodamine 123 among nine MXR/BCRP/ABCP-overexpressing cells studied; all demonstrated mitoxantrone transport, whereas only two effluxed rhodamine 123...
  11. ncbi TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
    Stephane Oudard
    Hopital Europeen Georges Pompidou, Universite Paris Descartes, Paris 5, 20 rue Leblanc, Paris, France
    Future Oncol 7:497-506. 2011
    ..Future development of this therapy and others under investigation is discussed...
  12. pmc Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis
    Coralie Chanvillard
    Experimental and Clinical Research Center, Charité Medical Faculty, Berlin, Germany
    PLoS ONE 7:e39625. 2012
    b>Mitoxantrone is one of the few drugs approved for the treatment of progressive multiple sclerosis (MS). However, the prolonged use of this potent immunosuppressive agent is limited by the appearance of severe side effects...
  13. ncbi 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice
    Guohua An
    Department of Pharmaceutical Sciences School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, 517 Hochstetter Hall, Amherst, New York 14260 1200, USA
    Pharm Res 28:1090-9. 2011
    The objective of our study was to investigate the effect of 5,7-DMF on the accumulation of mitoxantrone (MX) in BCRP-expressing normal cells and to investigate its impact on the PK and tissue distribution of MX in mice.
  14. ncbi Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines
    A Vogelgesang
    Department of Neurology, University of Greifswald, Greifswald, Germany
    Acta Neurol Scand 122:237-43. 2010
    b>Mitoxantrone is a cytotoxic drug with immune modulatory properties used in the treatment of progressive forms of multiple sclerosis (MS)...
  15. ncbi Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone
    Hiroshi Kodaira
    Pharmacokinetic Research Laboratories, Research Division, Kyowa Hakko Kirin Co, Ltd, Shizuoka, Japan
    J Pharmacol Exp Ther 333:788-96. 2010
    ..The C(brain)/C(plasma) and C(testis)/C(plasma) of the common substrates erlotinib, flavopiridol, and mitoxantrone were markedly increased in Mdr1a/1b(-/-)/Bcrp(-/-) mice even compared with Mdr1a/1b(-/-) and Bcrp(-/-) mice...
  16. ncbi The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)
    T Litman
    National Cancer Institute, Medicine Branch, National Institutes of Health, Bethesda, MD 20892, USA
    J Cell Sci 113:2011-21. 2000
    ..We sought to characterize the phenotype of the newly discovered ABC transporter encoded by the mitoxantrone resistance gene, MXR, also known as ABCP1 or BCRP...
  17. ncbi Mechanism of action of mitoxantrone
    Edward J Fox
    MS Clinic of Central Texas, 7200 Wyoming Springs Dr, Suite 1100, Round Rock, TX 78681, USA
    Neurology 63:S15-8. 2004
    b>Mitoxantrone, a synthetic anthracenedione, was developed in the 1980s as a doxorubicin analogue in a program to find a cytotoxic agent with decreased cardiotoxicity compared with doxorubicin...
  18. ncbi Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
    R Ellis
    Walton Centre for Neurology and Neurosurgery, Neurological Sciences, Liverpool, UK
    Mult Scler 15:505-8. 2009
    ..Therapy-related acute leukaemia (TRAL) is a concern for neurologists and patients when considering treatment with Mitoxantrone for multiple sclerosis (MS)...
  19. ncbi Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica
    Su Hyun Kim
    Department of Neurology, Research Institute and Hospital of National Cancer Center, Korea
    Arch Neurol 68:473-9. 2011
    To evaluate the efficacy and safety of mitoxantrone hydrochloride and determine how it exhibits a differential inhibitory effect on subsets of B cells in patients with highly relapsing neuromyelitis optica (NMO).
  20. ncbi Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes
    K Miyake
    Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 59:8-13. 1999
    Reports of multiple distinct mitoxantrone-resistant sublines without overexpression of P-glycoprotein or the multidrug-resistance associated protein have raised the possibility of the existence of another major transporter conferring drug ..
  21. pmc Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients
    A Chan
    Department of Neurology, Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Julius Maximilians University, Wurzburg, Germany
    Clin Exp Immunol 139:152-8. 2005
    b>Mitoxantrone (MX) is a cytotoxic drug with proven clinical efficacy in active multiple sclerosis (MS). In this ex vivo study we investigated the immunological effects of MX on peripheral blood leucocytes (PBL) from MS patients...
  22. ncbi Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells
    R W Robey
    Developmental Therapeutics Department, Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 7:145-52. 2001
    ..nM flavopiridol and was found to be 24-fold resistant to flavopiridol, as well as highly cross-resistant to mitoxantrone (675-fold), topotecan (423-fold), and SN-38 (950-fold), the active metabolite of irinotecan...
  23. ncbi Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer
    Ana Catarina Pinto
    Faculty of Pharmacy, Laboratory of Pharmaceutical Technology, University of Coimbra, Coimbra, Portugal
    Prostate 71:81-90. 2011
    b>Mitoxantrone plus prednisone is a palliative treatment for hormone-refractory prostate cancer (HRPC) but without survival benefit. Imatinib has shown activity against HRPC but only in the preclinical setting...
  24. pmc The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone
    Mark F Rosenberg
    Manchester Interdisciplinary Biocentre, 131 Princess Street, University of Manchester, Manchester, M1 7DN, UK
    Structure 18:482-93. 2010
    ..Two crystal forms with and without mitoxantrone were observed with unit cell dimensions of a = 55.4 A, b = 81.4 A, gamma = 89.8 degrees , and a = 57...
  25. pmc Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: a versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV
    Rainer Tietze
    Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich Alexander University Erlangen Nurnberg, Section for Experimental Oncology and Nanomedicine Else Kröner Fresenius Foundation Professorship, 91054 Erlangen, Germany
    J Biomed Biotechnol 2010:597304. 2010
    ..We here present an analytical method (HPLC-UV), to detect pure or ferrofluid-bound mitoxantrone in a complex matrix even in trace amounts in order to perform biodistribution studies...
  26. ncbi A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)
    R W Robey
    Developmental Therapeutics Department, Medicine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Biochim Biophys Acta 1512:171-82. 2001
    The fluorescent compounds rhodamine 123, LysoTracker Green DMD-26, mitoxantrone, and BODIPY-prazosin were used with the antagonist fumitremorgin C (FTC) in order to develop functional assays for the half-transporter, MXR/BCRP/ABCP1...
  27. ncbi Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone
    K U Chow
    Johann Wolfgang Goethe University Hospital, Department of Medicine III, Hematology Oncology, Frankfurt, Germany
    Leuk Lymphoma 36:559-67. 2000
    ..The combination of 2-CdA with doxorubicin or mitoxantrone had a synergistic effect on the induction of apoptosis (p<0...
  28. ncbi Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study
    E Le Page
    CHU Pontchaillou, Service de Neurologie, Rennes, France
    Mult Scler 17:867-75. 2011
    ..From 2001, a French multicentre study was conducted prospectively in a large cohort of MS patients and annually updated up to at least 5 years after initiation of MITOX therapy...
  29. ncbi MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2)
    Meng Tao Ma
    Department of Pharmacology, China Medical University, North 2nd Road 92, Heping District, Shenyang 110001, Liaoning Providence, PR China
    Cancer Lett 339:107-15. 2013
    ..Therefore, after confirming that BCRP was increased in the mitoxantrone (MX)-resistant MCF-7 breast cancer cell line MCF-7/MX compared with its parental sensitive MCF-7 cell line, we ..
  30. ncbi Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
    V Martinelli
    Department of Neurology, INSPE, San Raffaele Scientific Institute, Milan, Italy
    Neurology 77:1887-95. 2011
    To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics.
  31. pmc Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
    F Paul
    J Neurol Neurosurg Psychiatry 78:198-200. 2007
  32. ncbi Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone
    Jakub Hofman
    Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic
    Pharmacol Res 65:312-9. 2012
    ..combination index method of Chou-Talalay, we confirmed that the strongest inhibitors, purvalanol A and olomoucine II, can synergistically potentiate cytostatic effect of mitoxantrone, an ABCG2 substrate, in ABCG2 expressing cell lines.
  33. ncbi Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein
    Glaucio Valdameri
    Equipe Labellisée Ligue 2011, Institut de Biologie et Chimie des Proteines, BMSSI UMR 5086, CNRS Université Lyon 1, Lyon, France
    J Med Chem 55:966-70. 2012
    ..The chromone derivative specifically inhibited ABCG2 versus other multidrug ABC transporters and was not transported. It constitutes a highly promising candidate for in vivo chemosensitization of ABCG2-expressing tumors...
  34. ncbi Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models
    Xiaowei Xie
    Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Urol 175:1926-31. 2006
    We explored the efficacy of the ginsenoside Rh2 and examined its impact on the effective dose of paclitaxel and mitoxantrone in the LNCaP prostate tumor model.
  35. ncbi Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone
    Charles J Ryan
    University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Cancer Res 19:215-24. 2013
    ..and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (HGF)/scatter factor, combined with mitoxantrone and prednisone (MP) in patients with castration-resistant prostate cancer (CRPC).
  36. ncbi Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
    Agnieszka Wierzbowska
    Department of Hematology, Medical University, Lodz, Poland
    Eur J Haematol 80:115-26. 2008
    ..effect of Ara-C in leukemic blasts and inhibit DNA repair mechanisms; therefore its association with Ara-C and mitoxantrone (MIT) results in a synergistic effect...
  37. ncbi Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein
    Glaucio Valdameri
    Equipe Labellisée Ligue, Institut de Biologie et Chimie des Protéines FR, Universite Lyon, Lyon, France
    ACS Chem Biol 7:322-30. 2012
    ..Here, various methoxy derivatives of resveratrol are shown to be potent inhibitors of mitoxantrone efflux by ABCG2: among a series of 11 derivatives, compound 9 (3,5,3',4'-tetramethoxy trans-stilbene) had an IC(..
  38. ncbi Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer
    Mark T Fleming
    US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA
    Clin Genitourin Cancer 10:6-14. 2012
    ..The efficacy of combining cetuximab with mitoxantrone (M) plus prednisone (MP) was evaluated in progressive metastatic castrate-resistant prostate cancer (CRPC) ..
  39. pmc Effects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomes
    Jie Zhuang
    School of Pharmacy, China, Pharmaceutical University, Nanjing, China
    Int J Nanomedicine 5:407-16. 2010
    ..this work was to evaluate the physical properties and in vivo circulation of chitosan (CH)-coated liposomes of mitoxantrone (MTO)...
  40. ncbi Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study
    Dominik R Berthold
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 14:2763-7. 2008
    The TAX-327 study randomized 1,006 men with metastatic hormone-refractory prostate cancer to receive 3-weekly docetaxel, weekly docetaxel, or mitoxantrone, each with prednisone.
  41. ncbi Rationale for the use of mitoxantrone in multiple sclerosis
    Gilles Edan
    Department of Neurology, Rue Henri Le Gallous, CHU Rennes, F 35700 Rennes, France
    J Neurol Sci 223:35-9. 2004
    b>Mitoxantrone is a member of the anthracendione family developed to treat malignancies and increasingly used to treat multiple sclerosis (MS)...
  42. ncbi The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria
    Annemarie Wehenkel
    Unité de Biochimie Structurale and CNRS URA2185, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris, France
    FEBS Lett 580:3018-22. 2006
    ..Here, we demonstrate that mitoxantrone, an anthraquinone derivative used in cancer therapy, is a PknB inhibitor capable of preventing mycobacterial ..
  43. pmc Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10
    Franco Mandelli
    Department of Cellular Biotechnologies and Hematology, SapienzaUniversity, Rome, Italy
    J Clin Oncol 27:5397-403. 2009
    ..To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML)...
  44. ncbi The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells
    Yonggang Ma
    University of Heidelberg, Institute of Pharmacy and Molecular Biotechnology, INF 364, 69120 Heidelberg, Germany
    Phytother Res 24:146-9. 2010
    ..Harmine reduced resistance to the anticancer drugs mitoxantrone and camptothecin mediated by BCRP and might be an interesting new reversal agent...
  45. ncbi The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models
    Pauline Breedveld
    Department of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Mol Pharmacol 71:240-9. 2007
    ..cells: we found a 3-fold higher level of resistance to both methotrexate and the prototypical BCRP substrate mitoxantrone at pH 6.5 as at physiological pH...
  46. pmc Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone)
    Suxin Zheng
    Department of Chemistry, University of Washington, Seattle, 98195, USA
    Chem Biol 16:557-66. 2009
    ..The anticancer drug mitoxantrone was recently identified in a high throughput screen to stabilize the tau pre-mRNA stem loop...
  47. pmc Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
    Catriona Parker
    Cancer Research UK Children s Cancer Group, School of Cancer and enabling Sciences, University of Manchester, Manchester Academic Health Science Centre, Central Manchester University Hospitals Foundation Trust, Manchester, UK
    Lancet 376:2009-17. 2010
    ..We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens...
  48. ncbi Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial
    G Edan
    Department of Neurology, University Hôpital Pontchaillou, Centre Hospitalier Universitaire, Service de Neurologie, Rennes, France
    J Neurol Neurosurg Psychiatry 82:1344-50. 2011
    The long-term impact of interferon-beta-1b (IFN) might be improved by short-term immunosuppression with mitoxantrone (MITOX) in aggressive relapsing-remitting multiple sclerosis (ARMS) patients.
  49. ncbi Mitoxantrone: a review of its use in multiple sclerosis
    Lesley J Scott
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:379-96. 2004
    b>Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent...
  50. pmc Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins
    Zahra Hajihassan
    Department of Biochemistry, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
    J Biomed Sci 16:31. 2009
    b>Mitoxantrone is a potent antitumor drug, widely used in the treatment of various cancers...
  51. ncbi Mitoxantrone: benefits and risks in multiple sclerosis patients
    V Martinelli
    Neurology Department, INSPE, University IRCCS San Raffaele, Milan, Italy
    Neurol Sci 30:S167-70. 2009
    b>Mitoxantrone (MTX) is a synthetic antineoplastic cytotoxic drug, active both on proliferative and non-proliferative cells...
  52. ncbi Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)
    Bianca Weinstock-Guttman
    The William C Baird Multiple Sclerosis Center, Jacobs Neurological Institute, State University of New York, Buffalo, NY 14203, USA
    Arch Neurol 63:957-63. 2006
    ..It is considered to have a B-cell-induced pathogenesis. Mitoxantrone hydrochloride, a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis and ..
  53. ncbi Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group
    M Unterhalt
    Dept of Hematology and Oncology, University of Gottingen, Germany
    Leukemia 10:836-43. 1996
    The current study was initiated to compare the anti-lymphoma activity and side-effects of prednimustine/mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) in patients with advanced low-grade non-Hodgkin's lymphomas in ..
  54. ncbi Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11
    Hellinida Thomadaki
    Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, 15701 Athens, Greece
    Thromb Haemost 101:373-80. 2009
    ..the mRNA expression levels of KLK5 and KLK11 genes in prostate cancer cells PC3 as a response to treatment with mitoxantrone, etoposide, doxorubicin and carboplatin...
  55. pmc Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    James J Marriott
    The Multiple Sclerosis Clinic, St Michael s Hospital, Division of Neurology, University of Toronto, Canada
    Neurology 74:1463-70. 2010
    The chemotherapeutic agent mitoxantrone was approved for use in multiple sclerosis (MS) in 2000...
  56. ncbi Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
    D R Berthold
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Ann Oncol 19:1749-53. 2008
    The TAX 327 study compared 3-weekly docetaxel, weekly docetaxel or 3-weekly mitoxantrone, each with prednisone, for 1006 patients with metastatic hormone-refractory prostate cancer...
  57. pmc Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 117:3302-10. 2011
    ..Flavopiridol given by 1-hour bolus at 50 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active in adults with poor-risk acute leukemias...
  58. pmc Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone
    Daniel J Smart
    Department of Pathology, New York Medical College, Valhalla, NY 10595, USA
    Mutat Res 641:43-7. 2008
    ..induction of gammaH2AX in relation to DSBs induced by topoisomerase II (TOPO II) poisons, etoposide (ETOP) and mitoxantrone (MXT), in V79 cells...
  59. ncbi Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release
    Chunlei Li
    Zhongqi Pharmaceutical Technology, Shijiazhuang, Co Ltd, No 276, ZhongShan West Road, Shijiazhuang City, Hebei Province 050051, PR China
    Eur J Pharm Sci 34:333-44. 2008
    ..To explore the role of anions in metal ion gradient method, copper ion-mediated mitoxantrone (MIT) loading was investigated systematically...
  60. ncbi Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
    G L Scheffer
    Department of Pathology, Free University Hospital, Amsterdam, The Netherlands
    Cancer Res 60:2589-93. 2000
    ..In this study, we describe a BCRP-specific monoclonal antibody, BXP-34, obtained from mice, immunized with mitoxantrone-resistant, BCRP mRNA-positive MCF-7 MR human breast cancer cells...
  61. ncbi Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin
    Pornngarm Limtrakul
    Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    Mol Cell Biochem 296:85-95. 2007
    ..the effect of tetrahydrocurcumin (THC) on three ABC drug transporter proteins, P-glycoprotein (P-gp or ABCB1), mitoxantrone resistance protein (MXR or ABCG2) and multidrug resistance protein 1 (MRP1 or ABCC1) was investigated, to ..
  62. ncbi Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab
    Judith E Karp
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 10:3577-85. 2004
    ..We conducted a Phase II clinical trial of bevacizumab administered after chemotherapy to adults with refractory or relapsed AML, using a timed sequential therapy (TST) approach...
  63. ncbi Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2
    Ahcene Boumendjel
    Departement de Pharmacochimie Moleculaire, UMR 5063 CNRS Université Joseph Fourier Grenoble I, 5 Avenue de Verdun BP 138, 38243 Meylan, France
    Bioorg Med Chem 15:2892-7. 2007
    ..One of the acridones was even more potent than the reference inhibitor, GF120918, as shown by its ability to inhibit mitoxantrone efflux.
  64. ncbi Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
    Thomas Buchner
    Department of Medicine, Hematology Oncology, University of Muenster, Muenster, Germany
    J Clin Oncol 24:2480-9. 2006
    ..Whether additional intensification can add to this effect has not yet been determined...
  65. ncbi Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin
    Xuan Huang
    Brander Cancer Research Institute, New York Medical College, Valhalla, New York 10532, USA
    Cytometry A 58:99-110. 2004
    ..The purpose of this study was to further characterize the drug-induced (DI) IF of gammaH2AX, and in particular to distinguish it from AA gammaH2AX IF triggered by DNA breaks that occur in the course of AA DNA fragmentation...
  66. ncbi Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone
    Donna L Berry
    University of Washington, Seattle, WA 98195 7266, USA
    J Clin Oncol 24:2828-35. 2006
    ..be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)...
  67. ncbi Chemotherapy for prostate cancer
    Timothy Gilligan
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 60:94-100; discussion 100. 2002
    ..The early studies combining mitoxantrone plus a corticosteroid demonstrated that chemotherapy could be given to men with symptomatic hormone-refractory ..
  68. pmc Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
    Yingna He
    Key Laboratory of Biomedical Material of Tianjin, Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China
    Int J Nanomedicine 5:697-705. 2010
    A sterically stabilized, mitoxantrone-loaded liposome, tailored to target luteinizing hormone-releasing hormone (LHRH) receptor overexpressing cells, was developed to promote the efficiency of intracellular delivery of mitoxantrone ..
  69. ncbi Toxicity of the topoisomerase II inhibitors
    Karen Seiter
    New York Medical College, Room 250 Munger Pavilion, Valhalla, New York 10595, USA
    Expert Opin Drug Saf 4:219-34. 2005
    ..Topoisomerase II inhibitors include the anthracyclines, mitoxantrone and epipodophyllotoxins. Short-term toxicity includes myelosuppression and gastrointestinal toxicity...
  70. ncbi Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment
    Christoph Alexiou
    Department of Otorhinolaryngology, Head and Neck Surgery, University Erlangen Nurnberg, Germany
    J Drug Target 11:139-49. 2003
    ..b>Mitoxantrone was quantitatively measured using HPLC-analysis. The strength of the external magnetic field was 0...
  71. ncbi The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
    J D Allen
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam
    Cancer Res 59:4237-41. 1999
    ..cell lines lacking functional Mdr1a, Mdr1b, and Mrp1 genes were selected for resistance to topotecan, mitoxantrone, or doxorubicin...
  72. ncbi 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by seq
    Thomas Buchner
    University Medical Center, Department of Medicine, Hematology and Oncology, University of Muenster, Ulbert Schweitzer Str 33, D 48129 Muenster, Germany
    J Clin Oncol 21:4496-504. 2003
    ..To examine the efficacy of prolonged maintenance chemotherapy versus intensified consolidation therapy for patients with acute myeloid leukemia (AML)...
  73. ncbi Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein
    Young Joo Lee
    Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 0033, Japan
    J Pharmacol Exp Ther 312:44-52. 2005
    ..involvement of Bcrp in the efflux transport of typical substrates, dehydroepiandrosterone sulfate (DHEAS) and mitoxantrone, across the mouse BBB...
  74. ncbi Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance
    Ilan Ifergan
    Department of Biology, Technion Israel Institute of Technology, Haifa, Israel
    Cancer Res 65:10952-8. 2005
    ..ABCG2 in the plasma membrane of cancer cells confers resistance to various anticancer drugs, including mitoxantrone. Here, we explored the mechanism underlying drug resistance in the MCF-7 breast cancer sublines MCF-7/MR and ..
  75. pmc A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy
    Hui Peng
    Department of Pharmacology and Toxicology, University School of Medicine, Indianapolis, Indiana, United States of America
    PLoS ONE 4:e5676. 2009
    ..Knockout of ABCG2 had no apparent adverse effect on the mice. Thus, ABCG2 is an ideal target for development of chemo-sensitizing agents for better treatment of drug resistant cancers and helping eradicate cancer stem cells...
  76. ncbi ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis
    S Cotte
    Institute for MS research, Medical Faculty, University of Göttingen and Gemeinnützige Hertie Stiftung, Gottingen, Germany
    Brain 132:2517-30. 2009
    Escalation therapy with mitoxantrone (MX) in highly active multiple sclerosis is limited by partially dose-dependent side-effects. Predictors of therapeutic response may result in individualized risk stratification and MX dosing...
  77. ncbi Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line
    Jing Wang
    State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510 060, P R China
    Cancer Res 67:3716-24. 2007
    ..Taken together, our data shed light on tumorigenesis and therapeutic-resistant mechanisms, which are helpful for developing novel targets for effective clinical treatment of NPC...
  78. ncbi Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501
    William S Velasquez
    University of Texas Medical Branch, Galveston, USA
    J Clin Oncol 21:1996-2003. 2003
    To determine the efficacy of combination fludarabine and mitoxantrone (FN) in untreated stages III and IV low-grade lymphoma. The major end point was to estimate progression-free survival (PFS) in all eligible patients.
  79. ncbi Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer
    Marie Cecile Le Deley
    Biostatistics and Epidemiology Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 25:292-300. 2007
    ..To determine the risk factors for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer...
  80. pmc Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer
    Mark Garzotto
    Division of Urology, Oregon Health and Science University, Portland Veterans Administration Medical Center, Portland, Oregon, USA
    Cancer 116:1699-708. 2010
    ..Secondary endpoints included safety, pathologic effects of chemotherapy, and predictors of disease recurrence...
  81. ncbi Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment
    Xiaobin Zhao
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    J Pharm Sci 97:1508-18. 2008
    ..In vitro and clinical studies have indicated advantages when FLU and mitoxantrone (MTO) are applied in combination...
  82. ncbi Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival
    Richard A Burkhart
    Thomas Jefferson University, 1015 Walnut Street, Curtis 611A, Philadelphia, PA 19107, USA
    Mol Cancer Res 11:901-11. 2013
    ..An in vitro drug sensitivity assay demonstrated that one of these USP11 inhibitors, mitoxantrone, impacted PDA cell survival with an IC50 of less than 10 nM...
  83. ncbi A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
    K N Chi
    Vancouver Cancer Centre, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada, V5Z 4E6
    Clin Cancer Res 7:3920-7. 2001
    ..In this dose escalation study, we evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with HRPC.
  84. ncbi Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy
    C Buhmann
    Department of Neurology, University Hospital Eppendorf, Hamburg, Germany
    Acta Neurol Scand 106:236-9. 2002
    ..In a 4-year follow-up during immunosuppressive therapy with mitoxantrone, we found a remarkable time delayed visual recovery 12 months after acute onset of rapid sequential bilateral ..
  85. ncbi Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients
    M Adamczyk-Sowa
    Department of Neurology, Medical University of Silesia, Zabrze, Poland
    J Physiol Pharmacol 63:683-90. 2012
    b>Mitoxantrone (MX) is approved for the treatment of aggressive relapsing-remitting, secondary-progressive and progressive-relapsing form of multiple sclerosis (MS)...
  86. ncbi The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
    T Jock Murray
    MS Research Unit, Dalhousie University, Halifax, Nova Scotia, B3H 1V7, Canada
    Expert Opin Drug Saf 5:265-74. 2006
    b>Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) ..
  87. ncbi Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer
    Ali Reza Montazerabadi
    Department of Medical Physics, Tehran University of Medical Sciences, Tehran, Iran
    Photodiagnosis Photodyn Ther 9:46-51. 2012
    ..The purpose of this study was to assess the effectiveness of mitoxantrone, a chemotherapeutic agent, as a photosensitizer for photodynamic therapy in the MCF-7 human breast cancer cell ..
  88. ncbi The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity
    E H Herman
    Division of Applied Pharmacology Research, Center for Drug Evaluation and Research, Food and Drug Administration, Laurel, MD 20708, USA
    Cancer Chemother Pharmacol 48:297-304. 2001
    To compare the protective effect of dexrazoxane (DRZ) against cardiotoxicity induced by doxorubicin (DXR) and mitoxantrone (MTX).
  89. ncbi Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts
    Suresh Radhakrishnan
    Centre for Molecular Oncology and Imaging, Institute of Cancer, Barts and London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, United Kingdom
    Hum Gene Ther 21:1311-25. 2010
    ..mutants in combination with the current standard of care for late-stage hormone-independent prostate cancers, mitoxantrone or docetaxel...
  90. ncbi [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients]
    E Le Page
    Service de Neurologie, Hopital Pontchaillou, Rennes
    Rev Neurol (Paris) 162:185-94. 2006
    On the basis of the French and British (FB) MS Trial, Mitoxantrone (MITOX) was approved by the AFSAPPS in October 2003 in patients with aggressive multiple sclerosis (MS), given as induction therapy monthly for 6 months (ELSEP)...
  91. ncbi In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients
    Francesco Angelucci
    Department of Neuroscience, Institute of Neurology, Catholic University, Rome, Italy
    Neuroimmunomodulation 13:76-81. 2006
    b>Mitoxantrone is an antineoplastic agent also used for the treatment of multiple sclerosis (MS). However, despite its efficacy, few data are available on its mechanism of action...
  92. ncbi Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma
    Markus Raderer
    Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Oncology 70:411-7. 2006
    ..As no data on this topic exist for MALT lymphoma, we have retrospectively analysed our experience with R plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone (R-CHOP/R-CNOP) in patients with relapsed MALT lymphoma.
  93. ncbi Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma
    Nozomi Niitsu
    Hematology Division Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Saitama 350 0495, Japan
    Cancer Sci 97:933-7. 2006
    ..The R-CMD regimen was safe in elderly patients with DLBCL. No new signs of cardiotoxicity were observed with this regimen. It was also effective in patients with relapsed or refractory DLBCL who had previously used DXR...
  94. ncbi Combination therapy of percutaneous mitoxantrone injection, percutaneous ethanol injection, and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastasis
    T Kiba
    Third Department of Internal Medicine, Yokohama City University School of Medicine, 3 9 Fukuura, Kanazawa Ku, Yokohama 236, Japan
    Hepatogastroenterology 48:427-31. 2001
    ..and left adrenal metastasis with the combination approach of percutaneous intratumoral chemotherapy with mitoxantrone, percutaneous ethanol injection, and transcatheter arterial embolization...
  95. ncbi Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades
    Murielle Mimeault
    Department of Biochemistry and Molecular Biology, College of Medicine, Eppley Institute of Cancer and Allied Diseases, 985870 University of Nebraska Medical Center, Omaha, NE 68198 5870, USA
    Growth Factors 25:400-16. 2007
    The results of the present study revealed for the first time the possibility to use a combination of mitoxantrone with gefitinib and cyclopamine for inhibiting the growth of epidermal growth factor (EGF), sonic hedgehog- (SHHNp), and ..
  96. ncbi Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes
    Rae Sung Chang
    School of Life Sciences and Biotechnology, Korea University, Seoul, South Korea
    Nanomedicine 6:769-76. 2010
    ..We aimed to develop optimized liposomes for mitoxantrone (MTO) administration that provide high encapsulation efficiency and increase the therapeutic index...
  97. ncbi The study of mitoxantrone as a potential immunosuppressor in transgenic pig renal xenotransplantation in baboons: comparison with cyclophosphamide
    Joanna Ashton-Chess
    Institut de la Sante et de la Recherche Medicale, Unite 437, Institut de Transplantation et de Recherche en Transplantation, Centre Hospitalier Universitaire Hotel Dieu, Nantes, France
    Xenotransplantation 11:112-22. 2004
    ..we performed a preliminary study in baboons immunized against pig blood cells using the immunosuppressor mitoxantrone (Mx)...
  98. ncbi Mitoxantrone-loaded zeolite beta nanoparticles: preparation, physico-chemical characterization and biological evaluation
    Stefan Grund
    Department of Pharmaceutical Technology, Friedrich Schiller University of Jena, Otto Schott Strasse 41, D 07745 Jena, Germany
    J Colloid Interface Sci 365:33-40. 2012
    ..characterization of a new host-guest system consisting of zeolite beta nanoparticles as host and mitoxantrone as guest...
  99. ncbi Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia
    E Tse
    Leukemia 21:2225-6. 2007
  100. pmc Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice
    K M Rentsch
    Institute of Clinical Chemistry, , Switzerland
    Br J Cancer 75:986-92. 1997
    Two liposomal formulations of mitoxantrone (MTO) were compared with the aqueous solution (free MTO) in terms of their pharmacokinetic behaviour in ICR mice and cytotoxic activity in a nude mouse xenograft model...
  101. ncbi Spectral studies on the molecular interaction of anticancer drug mitoxantrone with CTAB micelles
    Mirela Enache
    I Murgulescu Institute of Physical Chemistry, Romanian Academy, Bucharest, Romania
    J Pharm Sci 100:558-65. 2011
    The interaction of anticancer drug mitoxantrone with cationic surfactant cetyltrimethylammonium bromide (CTAB) has been investigated by absorption spectroscopy as a function of surfactant concentration ranging from the premicellar to ..

Research Grants63

  1. Mechanism of action of TOP2-directed anticancer drugs
    Leroy F Liu; Fiscal Year: 2012
    ..Top2-targeting drugs such as etoposide (VP-16), doxorubicin and mitoxantrone are among the most effective and widely used anticancer drugs in the clinic...
  2. TARGETING AML-STROMAL INTERACTIONS
    John F DiPersio; Fiscal Year: 2013
    ..G-CSF+AMD3100 will be administered prior to mitoxantrone-etoposide-high dose Ara-C (MEC) salvage chemotherapy to optimally mobilize leukemic blasts, thus sensitizing ..
  3. Targeting Leukemia Stromal Interactions in AML
    Geoffrey L Uy; Fiscal Year: 2013
    ..inhibitor of CXCR4, to chemosensitize AML in a clinical trial entitled, "A phase l/ll study of AMD3100 plus mitoxantrone, etoposide, and cytarabine (AMD3100-I-MEC) in relapsed or refractory AML...
  4. Optical Imaging of Chemotherapy for Brain Tumors
    Shailendra Joshi; Fiscal Year: 2013
    ..Using mitoxantrone as the prototype chemotherapeutic drug, our goal is to utilize optical tools to better understand the ultra-..
  5. Cytoplasmic Reactivation of p53 Family Members
    Charles Walker; Fiscal Year: 2004
    ..of leukemic clam hemocytes after treatment with the topoisomerase II inhibitors - etoposide, doxorubicin and mitoxantrone. Our data suggest that p53- or p63/73-dependent mechanisms involved in cancers in these distantly related ..
  6. MUTAGENIC ACTION OF CANCER THERAPY ON TESTIS CELLS
    Marvin Meistrich; Fiscal Year: 1992
    ..We will utilize available monkeys from other studies to extend this observation to fractionate irradiations...
  7. MODULATION OF MULTIDRUG RESISTANCE MECHANISMS
    Branimir Sikic; Fiscal Year: 2002
    ..Planned studies include: PSC 833 (PSC)/Doxil/paclitaxel; LY335979/mitoxantrone; LY335979/doxorubicin/paclitaxel; and other, new MDR1 modulators...
  8. NEW MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER CELLS
    Erasmus Schneider; Fiscal Year: 2001
    ..a Pgp-and MRP-negative variant of the human breast cancer cell line MCF7, MCF7/MX, that has been selected for mitoxantrone resistance, exhibits unusual cross-resistance to several camptothecin analogs such as topotecan and irinotecan...
  9. PULSE THERAPY TRIAL IN BETA INTERFERON RESISTANT ACTIVE
    Derek Smith; Fiscal Year: 2003
    ..There is evidence that treatment of these patients with pulse methylprednisolone, pulse mitoxantrone or pulse cyclophosphamide may effectively reduce disease activity in these patients and potentially allow them ..
  10. DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
    Daniel Sullivan; Fiscal Year: 1992
    ..A paucity of information concerning the basis for mitoxantrone resistance exists...
  11. Novel Effects of DNA Intercalators: Inhibition of Epigenetic Modifications
    BETH VAN EMBURGH; Fiscal Year: 2009
    ..These studies were supported in this laboratory with both doxorubicin and mitoxantrone. Previous studies in this laboratory have discovered a novel function for doxorubicin as it is capable of ..
  12. Mechanism of Drug Transport by BCRP/ABCG2
    Qingcheng Mao; Fiscal Year: 2010
    ..Overexpression of BCRP in cancer cells is associated with resistance to multiple anticancer drugs, including mitoxantrone, topotecan, and flavopiridol...
  13. Effects of TPA on Leukemia and Solid Tumors
    Allan Conney; Fiscal Year: 2006
    ..D3, and butyrate), (b) inhibitors of NF-kappaB (BAY 11-7082) or (c) cytotoxic drugs (taxol, taxotere, mitoxantrone and estramustine) on proliferation and apoptosis of cultured human prostate cancer cell lines...
  14. A NEW CLASS OF DRUG CARRIERS FOR TREATMENT OF MS
    KENNETH KOSAK; Fiscal Year: 2003
    ..Two carriers will be synthesized and compared for efficacy. One will have mitoxantrone and the other cyclosporin an entrapped within it...
  15. ANNUAL MRI, MTR AND HMRSI IN HEALTHY CONTROLS AND PPMS
    Stephen Hauser; Fiscal Year: 2001
    ..in patients with primary progressive (PP)MS and healthy controls and, (2)determine the treatment effect of mitoxantrone on those imaging measures...
  16. TARGETING THE CXCR4-SDF1 AXIS AS THERAPY FOR RELAPSED/REFRACTORY AML
    John F DiPersio; Fiscal Year: 2010
    ..AMD3100 will be administered immediately prior to mitoxantrone-etoposide-high dose Ara-C (MEC) salvage chemotherapy, thus sensitizing the AML blasts to MEC chemotherapy...
  17. Two Photon Imaging of Drug Uptake Efflux & Modulation in MDR Tumor Cells in vivo
    AHMAD SAFA; Fiscal Year: 2007
    ..uptake, efflux and subcellular distribution of the highly fluorescent anticancer agents Adriamycin (ADR) and Mitoxantrone (MITOX) in human breast tumors maintained as xenografts in immuno-deficient mice...
  18. Targeting the oligomerization of human ABCG2
    Jian Ting Zhang; Fiscal Year: 2009
    ..P-glycoprotein (Pgp), multidrug resistance-associated proteinl (MRP1), and breast cancer resistance protein/mitoxantrone resistance protein (BCRP/MXR)...
  19. COLUMBIA UNIVERSITY SOUTHWEST ONCOLOGY GROUP PROGRAM
    Daniel Petrylak; Fiscal Year: 2003
    ..Based on substantial laboratory strength, we intend to integrate Columbia laboratory resources as core support for SWOG clinical studies. ..
  20. MRP/GST Synergy in MDR
    Charles Morrow; Fiscal Year: 2009
    ..2) Specific aim 2 examines the role of MRP1 and GSH in resistance to and transport of the anticancer drug mitoxantrone (MX)...
  21. A Novel Vitamin D Target in Human Prostate Cancer
    TOMASZ BEER; Fiscal Year: 2007
    ..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. [unreadable] [unreadable]..
  22. Targeting FLT3 as a Novel Specific Therapy for Leukemia
    Mark Levis; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  23. Oregon Prostate Cancer Conference 2001
    TOMASZ BEER; Fiscal Year: 2003
    ....
  24. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2009
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  25. Acupuncture for hot flashes in prostate cancer patients
    TOMASZ BEER; Fiscal Year: 2004
    ..The overall goal is to provide prostate cancer patients an effective, low toxicity, non-pharmacologic treatment modality for hot flashes. ..
  26. ANTITUMOR AGENTS AND THE BACTERIOPHAGE T4 TOPOISOMERASE
    Kenneth Kreuzer; Fiscal Year: 2001
    ..topoisomerase is sensitive to many of the antitumor agents that inhibit the mammalian enzyme, including m-AMSA, mitoxantrone, ellipticines and epipodophyllotoxins...
  27. Flow Instrument for Two-color Assay on Microtransponders
    Wlodek Mandecki; Fiscal Year: 2007
    ..The flow reader can be used for diagnostics in vitro and drug discovery projects. [unreadable] [unreadable] [unreadable]..
  28. IMMUNOREGULATORY T CELLS IN MULTIPLE SCLEROSIS
    Howard Weiner; Fiscal Year: 2005
    ..Our investigations will be greatly facilitated by our new Multiple Sclerosis Center with a large patient base and a dedicated MS MRI magnet and image analysis laboratory. ..
  29. Clinical application of multispectral imaging flow cytometry
    Hans Minderman; Fiscal Year: 2008
    ..The aim of the proposed studies is to determine necessary adjustments to this instrument's hardware and analysis software to accurately and efficiently use it in a clinical research setting. ..
  30. Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis
    Robert Fox; Fiscal Year: 2008
    ..Furthermore, these studies should help develop improved methods for evaluating new therapeutic strategies for neuroprotection and neuroregeneration. ..
  31. Ribosome-based Single Molecule Method to Acquire Sequence Data from Genomes
    Wlodek Mandecki; Fiscal Year: 2010
    ..The method can be used for nucleic acid diagnostics in vitro and in drug discovery. ..
  32. PEDIATRIC ONCOLOGY GROUP
    Yaddanapudi Ravindranath; Fiscal Year: 2002
    ....
  33. Cell Cycle Variants and Metastatic Prostate Cancer Risk
    Adam Kibel; Fiscal Year: 2009
    ..At the conclusion of this study, we will have a panel of markers that can be used to predict which patients are at high risk of treatment failure and eventual death from prostate carcinoma. ..
  34. Mucosal Immunotherapy in a mouse model of Alzheimer's Disease
    Howard L Weiner; Fiscal Year: 2010
    ..In this aim, we will investigate long term mucosal strategy to prevent and treat APP Tg mice using unique mucosal adjuvant combination given nasally and their ability to enhance amyloid clearance. ..
  35. Modulating P-glycoprotein to Enhance Neurodegenerative Drug Penetration of Brain
    CHRISTINE HRYCYNA; Fiscal Year: 2008
    ..Completion of these studies has the potential to improve treatment of epilepsy and Alzheimer's disease. [unreadable] [unreadable] [unreadable]..
  36. GENETIC PREDICTORS OF LEUKEMIA THERAPY RESPONSE
    Richard Aplenc; Fiscal Year: 2009
    ..This application will identify and validate polymorphisms that modify ALL therapy outcome and will rigorously evaluate the additional predictive information captured in genotype data. ..
  37. IN VIVO TREATMENT OF EAE WITH ANTI I-A ANTIBODIES
    Lawrence Steinman; Fiscal Year: 2001
    ..Aim 5 is to assess the possibility of using DNA vaccination against TCR Vb for treatment of EAE. It is hoped that these studies will provide the basis for future clinical trials in MS patients. ..
  38. ONS Research Agenda Conference
    Donna Berry; Fiscal Year: 2007
    ..The ONS Research Agenda will be evaluated after each conference from 2003-2007. [unreadable] [unreadable]..
  39. Ribonucleotide Reductase Antisense Strategy in AML
    Guido Marcucci; Fiscal Year: 2004
    ..It is expected that the analysis of these data will allow us to elucidate the intrinsic mechanisms of the antitumor activity of the antisense compounds and plan their incorporation in future therapeutic strategies for AML patients. ..
  40. Flow instrument for two-color assays on microtransponder
    Wlodek Mandecki; Fiscal Year: 2004
    ..The instrument will enable, in particular, a two-color expression profiling experiments as well as many other types of assays currently done on microarrays or flow cytometers. ..
  41. MR PREDICTORS OF RESPONSE TO HAART IN HIV DEMENTIA
    Joseph Berger; Fiscal Year: 2004
    ..It will also open novel avenues for exploring the differential sensitivities of these pathways to HAART, and suggest unique therapeutic options. ..
  42. Mentored Patient-Oriented Research Career Development Aw
    David Rizzieri; Fiscal Year: 2004
    ..These results will lead to future improvements in maximizing the anti-tumor effects of allogeneic therapy, hastening immunologic recovery, and minimizing the toxicity of this procedure. ..
  43. Personal Profile-Prostate:An Internet Decision Support
    Donna Berry; Fiscal Year: 2004
    ..After the programming is complete and the innovative web-based intervention is created, we will pilot test the program in 20 men with localized prostate cancer. ..
  44. EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRC
    Richard Rudick; Fiscal Year: 2003
    ..The expected outcome of this construction project will be a centralized facility to conduct innovative, collaborative clinical research protocols and train a new generation of physician scientists. ..
  45. Phase II Trial of Tetrathiomolybdate in Prostate Cancer
    David Smith; Fiscal Year: 2002
    ..The levels of these growth factors/cytokines will then be correlated with the degree of copper depletion, PSA level and response to therapy. ..
  46. NON-PROTEIN AMINO ACIDS AND TAXOID ANTITUMOR AGENTS
    Iwao Ojima; Fiscal Year: 2002
    ..Drug resistance in cancer chemotherapy is a serious problem. In order to solve this problem, the PI will continue his successful approach to the development of MDR reversal agents based on the strategic modification of baccatins. ..
  47. PEPTIDE MEDIATED IMMUNOTHERAPY FOR AUTOIMMUNE DISEASE
    Lawrence Steinman; Fiscal Year: 2003
    ..This work with APL may be applicable not only to MS, but to other autoimmune diseases including juvenile diabetes, rheumatoid arthritis, and inflammatory bowel disease. ..
  48. HIV Neuroprotection Workshop
    Joseph Berger; Fiscal Year: 2004
    ..The proposed conference is the first of its kind to highlight neuroprotection in HIV CNS and PNS disorders. By coupling this meeting with the International Symposium on Neurovirology this synergy can be exploited. ..
  49. NITROXIDERGIC CEREBROVASCULAR TONE DURING ANESTHESIA
    Shailendra Joshi; Fiscal Year: 2005
    ..abstract_text> ..
  50. Pregnancy and the Modulation of Multiple Sclerosis
    Annette Langer Gould; Fiscal Year: 2006
    ..The search for the pregnancy-related factor or hormone responsible for the protective effect of pregnancy in MS may potentially lead to the development of novel treatments for MS and other Th1-driven autoimmune diseases. ..
  51. Pharmacologic modulation of chromatin remodeling in leu*
    Guido Marcucci; Fiscal Year: 2006
    ..Further, we believe that this schedule is amenable to future combination-based approaches. [unreadable] [unreadable]..
  52. NURSING SUPPORT OF DECISIONS BY MEN WITH PROSTATE CANCER
    Donna Berry; Fiscal Year: 2002
    ..A prototype decision support aid will be developed and a pilot test conducted to guide men through the personal issues, expectations, and preferences to be considered in treatment decision-making after a diagnosis of prostate cancer. ..
  53. Fluidic Sorter for Microtransponders
    Wlodek Mandecki; Fiscal Year: 2005
    ..An automatic sorter would enable combinatorial chemistry on microtransponders, accelerating drug discovery. The sorter, in a parallel application, will also reduce the cost of microtransponder kits for DNA and protein multiplex assay. ..
  54. Evaluation of CYP24 as a Target for Enhancing Vitamin D*
    Donald Trump; Fiscal Year: 2006
    ..of apoptosis markers whether a relationship exists between modulation of these effects in vitro on tumor cells and a significant antitumor response in vivo in prostate, pancreatic and lung cancer models [unreadable] [unreadable]..
  55. IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE
    Adam Kibel; Fiscal Year: 2006
    ..The identification of a novel tumor suppressor would provide a target for better prostate cancer therapy and/or more accurate prognostic information for men newly diagnosed with the disease. ..
  56. INITIATION OF DNA REPLICATION IN THE PHAGE T4 SYSTEM
    Kenneth Kreuzer; Fiscal Year: 2005
    ....
  57. CARDINAL BERNARDIN CANCER CENTER, LOYOLA UNIVERSITY
    Patrick Stiff; Fiscal Year: 2002
    ..At the completion of this grant, the Cardinal Bernardin Cancer Center plans to be positioned to successfully apply for a P-30 Cancer Center Support Grant. ..
  58. Case/Cleveland Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2004
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. ..
  59. Direct analysis of fork blockage and DNA repair in vivo
    Kenneth Kreuzer; Fiscal Year: 2003
    ..If the system is validated, many other kinds of DNA damage can presumably be analyzed in-future studies. ..